Exposure to biologics, thiopurines or combination therapy for inflammatory bowel disease during pregnancy did not increase maternal or infant adverse events at birth or in 1-year of life, according to a study published in Gastroenterology.

“Practitioners should continue biologic and/or thiopurine therapy throughout pregnancy given no evidence of increase in harm from drug exposure and the clear association of active disease with adverse events,” Uma Mahadevan, MD, from the division of gastroenterology and hepatology at the University of California, San Francisco, and colleagues

Full Article: https://www.healio.com/news/gastroenterology/20210429/ibd-therapies-do-not-increase-adverse-events-in-pregnancy